This Incredibly Cheap Artificial Intelligence (AI) Stock Could Jump 8% as per Wall Street Analysts, But Don't Be Surprised to See It Soar Higher
The company delivered impressive growth in its revenue and earnings last quarter, and the trend is expected to continue.
The robust growth in this tech stock's earnings and its cheap valuation are reasons why investors should consider buying it right away.
10 stocks we like better than Lumentum ›
Lumentum Holdings (NASDAQ: LITE) stock took a beating so far in 2025. That's not surprising, considering the broader weakness in the stock market on account of macroeconomic headwinds caused by the tariff-fueled trade war.
However, the 9% drop in Lumentum stock this year doesn't seem justified if we consider that artificial intelligence (AI) has been driving a solid turnaround in the company's business. Lumentum is known for selling optical and photonics components that enable high-speed data transmission in communications networks and data centers, and the demand for its products has taken off thanks to AI.
This explains why the company's growth has been picking up in recent quarters. In the latest fiscal 2025 third-quarter earnings report (for the three months ended March 29), which was released on May 6, Lumentum easily beat expectations.
Let's see what's driving Lumentum's growth, and why it may be a good idea to buy this tech stock hand over fist right now.
Lumentum's fiscal Q3 revenue increased 16% year over year to $425 million, while its non-GAAP net income nearly doubled year over year to $0.57 per share. The company's cloud and networking business played a key role in driving this solid growth as it accounted for 86% of the company's top line. Lumentum's non-GAAP operating margin shot up to almost 11% from a slightly negative reading in the year-ago period, which explains the big jump in its bottom line.
Lumentum credits the big jump in its margins and earnings to an improvement in manufacturing utilization rates and a favorable product mix. The company is expecting its gross margin to improve on a sequential basis in the current quarter as well, despite an estimated negative effect of 100 basis points on account of tariffs.
Additionally, Lumentum says that "AI-driven cloud growth will continue to drive our financial momentum into Q4 and beyond" despite the macroeconomic headwinds caused by the tariff turmoil. That's not surprising, as demand for Lumentum's externally modulated lasers (EML), which are used in optical communications because of their ability to enable high-speed data transmission with high efficiency, increased because of AI.
Lumentum's EML shipments hit a record last quarter, and the company believes that it can double revenue from this product this year compared to June 2024 levels. Moreover, the company is increasing its manufacturing capacity of EMLs to support the strong demand for these components. Such a move could pay off in the long run, since sales of optical components used in AI clusters are expected to double from $5 billion last year to $10 billion next year.
As such, Lumentum is forecasting a significant acceleration in revenue. The company guided for revenue of $455 million in the current quarter at the midpoint of its guidance range, which would translate into a year-over-year increase of 48%. It's expecting non-GAAP earnings per share to land between $0.70 to $0.80 per share, which points toward a significant multiplication over the year-ago period's figure of $0.06 per share.
Lumentum carries a 12-month median price target of $82, as per 18 analysts covering the stock. That points toward an 8% jump from current levels. However, a sharp spike in Lumentum's earnings growth could eventually translate into much stronger gains. Analysts project an 88% increase in Lumentum's earnings for fiscal 2025 to $1.90 per share. The forecast for the next fiscal year is even stronger, followed by another impressive jump in fiscal 2027.
Assuming Lumentum manages to achieve $4.77 per share in earnings in fiscal 2027 and trades at 25 times earnings at that time (in line with the tech-laden Nasdaq-100 index's forward earnings multiple), its stock price could hit $120 in a couple of years. That points toward potential gains of 58% from current levels.
Given that Lumentum is trading at just 19 times forward earnings, investors can buy this AI stock at an attractive valuation right now before it takes off in the long run.
Before you buy stock in Lumentum, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lumentum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,951!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $796,353!*
Now, it's worth noting Stock Advisor's total average return is 948% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 12, 2025
Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool recommends Lumentum. The Motley Fool has a disclosure policy.
This Incredibly Cheap Artificial Intelligence (AI) Stock Could Jump 8% as per Wall Street Analysts, But Don't Be Surprised to See It Soar Higher was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
AST SpaceMobile (ASTS) Soars 20.86% on Planned Satellites Launch
We recently published AST SpaceMobile, Inc. (NASDAQ:ASTS) is one of the best-performing stocks on Tuesday. AST SpaceMobile snapped a four-day losing streak on Tuesday, jumping 8.36 percent after trading as much as 20.86 percent intra-day, as investor sentiment was bolstered by its plans to launch 60 satellites next year. 'We are confirming our fully-funded plan to deploy 45 to 60 satellites into orbit by 2026 to support continuous service in the US, Europe, Japan, and other strategic markets, including the US Government,' said AST SpaceMobile, Inc. (NASDAQ:ASTS) Chairman and CEO Abel Avellan in a statement. 'We also have planned orbital launches every one to two months on average during 2025 and 2026,' he added. Additionally, AST SpaceMobile, Inc. (NASDAQ:ASTS) is planning to deploy nationwide intermittent service in the US by the end of the year, followed by the UK, Japan, and Canada in the first quarter next year. This, alone, is expected to rake in revenues between $50 million and $75 million from government and commercial customers in the second half of the year. In the second quarter, AST SpaceMobile, Inc. (NASDAQ:ASTS) widened its net loss attributable to shareholders by 37 percent to $99.4 million from $72.5 million in the same period last year, despite revenues growing by 28 percent to $1.156 billion from $900 million year-on-year. Copyright: hywards / 123RF Stock Photo In the first half, attributable net loss grew by 57 percent to $145.1 million from $92.28 million in the same period last year, while revenues increased by 33.8 percent $1.874 billion from $1.4 billion year-on-year. While we acknowledge the potential of ASTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
3 minutes ago
- Yahoo
Paramount Skydance (PSKY) Gets 11% Boost from $7.7-Billion Exclusive UFC Deal
We recently published Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Tuesday. Paramount Skydance ended 8.4 percent higher on Tuesday after rallying as much as 11.5 percent at intra-day trade, with investor sentiment fueled by its bagging of $7.7-billion exclusive media rights to the Ultimate Fighting Championship (UFC). In a statement, Paramount Skydance Corp. (NASDAQ:PSKY) said it entered into an agreement with TKO Group Holdings, Inc., a premium sports and entertainment company, to exclusively air UFC for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. UFC is the world's premier mixed martial arts (MMA) organization. In the US alone, UFC has approximately 100 million fans who are highly engaged across linear, digital, and social platforms. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge
We recently published Liquidia Corp. (NASDAQ:LQDA) is one of the best-performing stocks on Tuesday. Liquidia rallied for a third straight day on Tuesday, ending 13.68 percent higher at $24.10 as investor sentiment was bolstered by the higher prescription rate for its newly approved pulmonary hypertension treatment, shunning a dismal earnings performance in the second quarter of the year. In an updated report, Liquidia Corp. (NASDAQ:LQDA) said its Yutrepia treatment, which was approved by the Food and Drug Administration (FDA) last May and was commercially launched in the first week of June, already registered as many as 900 unique patient prescriptions. 'The second quarter was a defining period for Liquidia with the FDA approval and rapid commercial launch of YUTREPIA inhalation powder. More than 350 physicians across the country have already prescribed YUTREPIA to treat patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), including those new to prostacyclin treatment or transitioning from Tyvaso, Tyvaso DPI, and even from oral prostacyclins,' said Liquidia Corp. (NASDAQ:LQDA) CEO Roger Jeffs. In other news, Liquidia Corp. (NASDAQ:LQDA) saw a 44.7-percent wider net loss in the second quarter of the year at $41.6 million versus $28.67 million in the same period last year. Revenues expanded by 144 percent to $8.8 million from $3.6 million in the same comparable period. While we acknowledge the potential of LQDA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
